Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Tenaya Therapeutics (NASDAQ: TNYA) announced it will present initial data from Cohort 1 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on December 17, 2024. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. The presentation will be accessible through the company's website, with a replay available afterward in the Investor Relations section.
Tenaya Therapeutics (NASDAQ: TNYA) ha annunciato che presenterà i dati iniziali del Cohort 1 dello studio clinico MyPEAK-1 Fase 1b/2 per la terapia genica TN-201 per l'ipertrofia cardiomiopatica associata a MYBPC3 (HCM) il 17 dicembre 2024. L'azienda ospiterà una call e un webcast alle 8:00 ET per discutere i risultati. La presentazione sarà accessibile attraverso il sito web dell'azienda, con una registrazione disponibile successivamente nella sezione Relazioni con gli Investitori.
Tenaya Therapeutics (NASDAQ: TNYA) anunció que presentará datos iniciales del Cohorte 1 del ensayo clínico MyPEAK-1 Fase 1b/2 de la terapia génica TN-201 para la cardiomiopatía hipertrófica asociada a MYBPC3 (HCM) el 17 de diciembre de 2024. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:00 a.m. ET para discutir los resultados. La presentación estará disponible a través del sitio web de la empresa, con una repetición disponible posteriormente en la sección de Relaciones con Inversores.
테나야 치료제 (NASDAQ: TNYA)는 MYBPC3 관련 비대 심근증(HCM)을 위한 TN-201 유전자 치료제의 MyPEAK-1 1b/2 단계 임상 시험의 Cohort 1에서 초기 데이터를 2024년 12월 17일 발표할 것이라고 발표했습니다. 회사는 결과를 논의하기 위해 동부 표준시 오전 8시에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 발표는 회사 웹사이트를 통해 접속할 수 있으며, 이후 투자자 관계 섹션에서 재생이 가능합니다.
Tenaya Therapeutics (NASDAQ: TNYA) a annoncé qu'elle présentera des données initiales de la Cohorte 1 de l'
Tenaya Therapeutics (NASDAQ: TNYA) gab bekannt, dass am 17. Dezember 2024 erste Daten aus der Kohorte 1 der MyPEAK-1 Phase 1b/2 klinischen Studie zur TN-201 Gentherapie für MYBPC3-assoziierte hypertrophe Kardiomyopathie (HCM) präsentiert werden. Das Unternehmen wird um 08:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Die Präsentation wird über die Website des Unternehmens zugänglich sein, mit einem späteren Zugriff auf die Wiederholung im Bereich Investorenbeziehungen.
- None.
- None.
Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17.
Conference Call and Webcast
Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be available under the "Events” section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com.
An archived replay of the webcast will be available on Tenaya’s website.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
FAQ
What data will Tenaya Therapeutics (TNYA) present from the MyPEAK-1 trial on December 17, 2024?
When and where can investors access Tenaya's (TNYA) MyPEAK-1 trial data presentation?
What is the therapeutic target of Tenaya's (TNYA) TN-201 gene therapy in the MyPEAK-1 trial?
Will there be a replay available of Tenaya's (TNYA) MyPEAK-1 trial data presentation?
